



INDEX OF AUTHORS*

Numbers in bold type indicate papers; numbers in roman type indicate contributions to discussions

- | | |
|--|---|
| <p>Ajello, L. 20, 23, 90, 93, 108, 109, 130, 142, 143, 162, 177, 192, 200, 252, 276, 277</p> <p>Austwick, P. K. C. 20, 92, 123, 175, 178, 197, 240, 268, 270, 272, 276, 277</p> <p>Baker, R. D. 9, 19, 22, 109, 111, 140, 141, 159, 178, 192</p> <p>Brygoo, E. R. 202, 204, 252</p> <p>Clark, Betty M. 111, 123, 179, 195, 196, 197</p> <p>Cockshott, W. P. 72, 110, 111, 113, 123, 124, 125, 127, 128, 252, 268</p> <p>Desai, S. C. 21, 48, 87, 89, 110, 111, 127, 128, 140, 141, 161, 177, 196, 253, 262, 266, 267</p> <p>Drouhet, E. 21, 49, 53, 74, 95, 109, 142, 161, 206, 251, 252, 263, 268, 270, 272, 277</p> <p>Edington, G. M. 2, 5, 19, 20, 25, 49, 51, 53, 73, 74, 89, 90, 93, 109, 110, 124, 128, 140, 141, 172, 176, 177, 178, 193, 195, 196, 197, 200, 252, 263, 266, 268, 270, 272, 273, 276, 278</p> <p>Emmons, C. W. 19, 21, 49, 142, 161, 162, 195, 197, 262, 266, 267, 268, 273, 275</p> <p>González Ochoa, A. 86, 159, 161, 162, 241, 252</p> <p>Hutt, M. S. R. 124, 177, 193, 196, 197, 273, 274, 275</p> | <p>Kashkin, P. N. 204, 264</p> <p>Lambo, T. A. I</p> <p>Lucas, A. O. 96, 108, 109, 110, 124, 129, 142, 195, 197, 201, 250, 251, 273</p> <p>Mackinnon, J. E. 22, 89, 143, 161, 162, 164, 175, 176, 178, 262, 266</p> <p>Mahgoub, E. S. 21, 72, 109, 125, 127, 142, 175, 193, 195, 240, 252, 265, 270</p> <p>Mariat, F. 22, 23, 49, 51, 89, 90, 127, 128, 129, 144, 161, 162, 175, 195, 241, 270, 275</p> <p>Murray, I. G. 73, 76, 78, 87, 89, 90, 91, 128, 141, 143, 176, 196, 204, 240, 241, 263</p> <p>Seeliger, H. P. R. 20, 22, 23, 49, 54, 72, 73, 74, 76, 85, 90, 141, 162, 175, 262, 265, 266, 275, 276</p> <p>Symmers, W. St. C. 20, 21, 22, 23, 26, 51, 53, 92, 93, 110, 128, 193, 196, 200, 201, 267, 273, 275, 276</p> <p>Utz, J. P. 124, 192, 196, 242, 250, 251, 267</p> <p>Vanbreuseghem, R. 21, 22, 25, 76, 87, 91, 93, 109, 124, 127, 128, 162, 176, 195, 251, 252, 263, 266, 272</p> <p>Winner, H. I. 20, 48, 73, 77, 91, 108, 128, 142, 143, 177, 200, 241, 250, 265</p> <p>Wolstenholme, G. E. W. 3</p> |
|--|---|

* Indexes compiled by Mr. William Hill

INDEX OF SUBJECTS

- Abdominal viscera, in histoplasmosis, 106, 121-122
- Abortion, mycotic in cattle, 178
- Abscesses, due to dematiaceous fungi, 274-275
- Absidia*, 23
- Actinomyces bovis*, 23, 131
- Actinomyces israelii*, 12, 15, 23, 48, 49
ecology and epidemiology, 130-131
- Actinomycetes*, causing mycetoma, 81
- Actinomycosis,
clinical features, 48, 99
club form, 49
incidence, 131, 142
pathogenesis, 12, 15
staining properties, 38
tissue reactions in, 36
transmission, 130-131, 137
treatment, 243, 265
- Aflatoxin, 25, 270
- African histoplasmosis, 12, 14
amphotericin B in, 251
clinical features, 101, 104-108, 124
diagnosis, 31, 106-107
immunological diagnosis, 58-60
incidence, 108, 109
microscopic appearances, 112
pulmonary, 123
radiological appearances, 113-123
treatment, 93, 110
- Allescheria boydii*, 12, 17, 31, 81, 82, 90, 116, 125, 215
- Amphotericin B,
action of, 131, 225, 228, 241, 244-246
administration, 223, 244-245
hydrocortisone and, 250-251
duration of treatment, 251-252
in African histoplasmosis, 251
in cryptococcal meningitis, 95, 244-245, 250, 251-252
in histoplasmosis, 93, 109
in North American blastomycosis, 244, 245
in phycomycosis, 196
physical and chemical properties, 213-214
- Amphotericin B—*continued*
resistance to, 220, 263
side effects, 245-246, 250
specific activity, 215, 216, 217
toxicity in animals, 226-227
- Antibiotics, *see also* Antifungal agents
antifungal spectrum, 210, 215
as predisposing factor for candidosis, 140-141
biological activities and mode of action, 206-241
categorization, 208-210
in vitro testing, 240-241, 254-258
polyene, 212-230
administration, 222-227
bioassay, 219
chemical structure and properties, 212-214
fungicidal activity, 218
fungistatic activity, 214-218
mode of action, 228-230
resistance to, 219-222
toxicity, 226
secondary properties of, 210
- Antifungal agents, *see also* Antibiotics
assessment, 253-263
clinical, 260-261
in vitro, 254-258
in vivo, 258-260
importance of route of administration, 268
problems of terminology, 253-254
- Aspergillosis, 193
epidemiology, 204
immunological diagnosis, 55, 61-63
in animals, 270
incidence, 277
microscopic appearances, 36
pathogenesis, 12, 16
radiological appearances, 114
staining methods for, 38
treatment, 223
- Aspergillus bouffardii*, 23
- Aspergillus flavus*, 31
- Aspergillus fumigatus*, 12, 20
identification, 49

- Aspergillus fumigatus*—continued
immunological properties, 61-63, 68, 72
- Aspergillus nidulans*, 23
- Aspergillus* spp., 19, 21
nomenclature, 23
problems with staining, 95
- Asthma and fungi, 197
- Baikie, W. B., biography, 5-8
- Basidiobolus meristosporus*, 12, 16
- Basidiobolus* spp., 99, 179-180, 195
action of griseofulvin, 231
identification, 180, 181
morphology and habitat, 189, 197
- Biopsy,
in diagnosis, 30
in mycetoma, 80, 81, 87
dangers of, 87
- Blastomyces dermatitidis*, 12, 15, 31, 109
action of antibiotics on, 215, 216, 233, 234
ecology and epidemiology, 132-133
immunological properties, 60-61, 76
strains, 143
- Blastomyces* spp., nomenclature, 23
- Bone lesions,
in histoplasmosis, 104, 117, 124
in mycetoma, 97, 114-115, 126
radiological diagnosis of, 114-117
- Bovine farcy, 270
- Buruli ulcer, 194
- Calcification, in histoplasmosis, 11, 12, 112
- Candidin,
administration, 224
specific activity, 215, 216
toxicity, 226
- Candida albicans*, 12, 16
action of cyanein, 235
ecology and epidemiology, 131
experimental infection, 91-92
- Candida* spp.,
action of antibiotics, 215, 216
resistant strains, 219-220, 240
- Candidosis, 12, 16
5-fluorocytosine in, 248
following heart surgery, 141
iatrogenic factors, 140-141
immunological diagnosis, 63-64, 73, 76
incidence, 132, 141-142
microscopic appearances, 36
of kidney, 92
- Candidosis—continued
pathogenesis, 48
radiological appearances, 119
staining methods, 38
transmission, 131, 137
treatment, 223, 264-265
- Cardiovascular system, fungal lesions of, 122
- Central nervous system,
in cladosporiosis, 37, 39, 48
in cryptococcosis, 95, 122, 245, 250, 251
- Cephalosporium falciforme*, 97
- Cephalosporium recifei*, 97
- Cephalosporium* spp., 12, 17, 31, 81
- Cercospora apii*, 18, 21
- Cercosporamycosis, 18, 21
- Cheloidal blastomycosis, see Lobo's disease
- Chemotherapy, see Antibiotics
- Chromomycosis, 12, 17, 39, 201
causative organisms, 273-274
clinical features, 100
effect of temperature, 170-171
epidemiology, 202-203, 204
microscopic appearances, 37
treatment, 170-171, 217, 252
- Cladosporiosis, of central nervous system, 12, 17, 37, 39, 48-49, 201
- Cladosporium* spp., 12, 17, 203, 204
- Climatic conditions, and mycoses, 177, 178,
see also under specific mycoses
- Coccidioides immitis*, 12, 14
action of antibiotics, 215, 216, 235
factors for growth, 173
- Coccidioidomycosis,
amphotericin B in, 245
central nervous system lesions, 122
diagnosis, 31
epidemiology, 201
immunological diagnosis, 54, 56-57
microscopic appearances, 37
pathogenesis, 12, 14
radiological appearances, 119
saramycetin in, 233
staining methods, 39
treatment, 223, 264
- Cryptococcal granuloma, 31
- Cryptococcal meningitis, 95, 245, 250, 251
- Cryptococcosis, 95, 132
clinical features, 100
diagnosis, 31, 49
ecology and epidemiology, 133-134
effect of temperature on, 170

- Cryptococcosis—*continued*
 epidemiology, 142-143, 205
 5-fluorocytosine in, 248
 hamycin in, 248
 immunological diagnosis, 64-66
 in animals, 269
 incidence, 134
 microscopic appearances, 37, 40
 pathogenesis, 14-15
 radiological appearances, 117, 119
 staining methods, 39, 41
 transmission, 137
 treatment, 170, 211, 223
Cryptococcus neoformans, 12, 14, 91
 action of antibiotics, 215, 216, 234
 identification, 41, 43, 48, 49
 immunological reactions, 65
 Cyanein, 234-235
 Cycloheximide, 210-212, 215
- Dematiaceous fungi, 273-275
 Dermatophytes, producing systemic infections, 21
 Diagnosis,
 differential of fungal infections, 43-45
 immunological techniques, 54-77
 place of histological examination, 30-33, 43-45
 radiological, 113-125
- Ecology of mycoses, 130-143
 Endarteritis obliterans, 127
 Endogenous fungi, 130-132
Entomorphthora coronata, 12, 16, 99, 114, 184
 morphology and habitat, 189-190, 197
 Epidemiology of mycoses, 130-143, 197-205
 research approaches, 275-276
 Epizootic lymphangitis, 269
 Erythrocytes, action of polyene antibiotics on, 218-219
 Eulicin, 215
 Exogenous fungi, 132-138
- Filipin, 212, 213
 5-Fluorocytosine, 248
Fonsecaea spp., 12, 17
 Fungi
 opportunistic, 9-10, 19-21, 22-23
 structure in relation to antibiotic action, 207
 tissue reactions to, 33-40, 48-53
- Geotrichosis, 12, 18, 67
Geotrichum candidum, 12, 18
 Griseofulvin, 21, 230-233
 in mycetoma, 231, 241
 mode of action, 232-233
 resistance to, 263
 specific activity, 215, 217
- Hamycin, 247-248
 administration, 224
 specific activity, 262
 toxicity, 226
- Heart surgery, candidosis following, 141
 Histopathology,
 of deep seated fungal infections, 26-53
 of mycetoma, 81-82, 85
Histoplasma capsulatum, 10, 12, 20, 51, 101, 112, 175
 action of antibiotics on, 215, 216, 233, 234
 comparison with *H. duboisii*, 112
 experimental infection with, 93
 identification, 42, 43, 51, 200
 immunological reactions, 54, 57-60, 74
 inhalation of spores, 123-124
Histoplasma duboisii, 14, 31, 37, 39, 101, 102, 106, 108, 112
 inhalation of spores, 123-124
 portal of entry into body, 109
 skin testing, 109
Histoplasma farciminosum, 269, 270-272
 Histoplasmosis,
 accidental infection, 13-14
 acute disseminated, 13
 aetiology, 109
 African, *see* African histoplasmosis
 amphotericin B in, 245, 251, 264
 calcification in, 11, 12, 122
 chronic disseminated, 13
 climatic conditions and, 169-170
 diagnosis, 31
 ecology, 134-137, 143
 effect of humidity and temperature, 111, 168-170, 175
 epidemiology, 134-136, 137, 169, 197-198, 200, 201, 205
 hamycin in, 248
 in animals, 269, 272
 incidence, 9, 12, 277
 microscopic appearances, 37
 pathogenesis, 12-14, 20
 pulmonary, 13

- Histoplasmosis—*continued*
 radiological appearances, 113-123
 saramycetin in, 247, 267
 schistosomiasis and, 272-273
 staining methods, 39
 sulphonamides in, 243
 treatment, 223
- Humidity,
 effect on growth of fungi, 176
 histoplasmosis and, 111
- Hydrocephalus, 122
- Hydrocortisone, with amphotericin B,
 245-246, 249, 250-251
- 2-Hydroxystilbamidine, 243-244
- Hypersensitivity, sporotrichosis and, 155
- Immunofluorescence microscopy, 42
- Immunological techniques in diagnosis,
 54-77, 82-83, 85, 90
- Intravenous infusions, predisposing to
 candidosis, 140-141
- Kidney, *candida albicans* infection of, 92
- Lagosin, 212, 213
- Leptosphaeria senegalensis*, 12, 17, 31, 81, 82,
 97
- Loboa lobo*, 12, 15
- Lobo's disease, 12, 15, 22, 23, 168
- Lung lesions,
 in blastomycosis, 119, 133
 in candidosis, 119
 in coccidioidomycosis, 119
 in histoplasmosis, 106, 112, 119, 120-121,
 123
 in sporotrichosis, 178
- Lymphadenopathy, in African histoplas-
 mosis, 105
- Madura foot, *see* Mycetoma
- Madurella grisea*, 23, 81, 82, 97
- Madurella mycetomi*, 81, 82, 83, 84, 114, 125,
 126, 127
 action of antibiotics on, 215, 217, 231
 causing mycetoma, 97
 immunological identification, 83
- Moniliasis, *see* Candidosis
- Monosporiosis, immunological diagnosis,
 66-67
- Monosporium apiospermum*, 90, 215, *see also*
Allescheria boydii
- Mossy foot, 100
- Mucor* spp., 12, 16, 23
- Mucormycosis, *see* Phycomycosis
- Mycetoma, 12, 17
 action of antibiotics, 217
 age incidence, 79
 biopsy in, 81, 87
 bone lesions, 114-115
 clinical features, 97-99, 125
 definition, 78
 development, 10
 diagnosis, 79-83, 89-90, 97
 cultural methods in, 80-81, 85, 89
 histopathological methods in, 81-82,
 85
 immunological methods in, 66-67, 72,
 82-83, 85, 90
 effect of griseofulvin, 231
 effect of temperature, 171-172
 epidemiology, 199, 204
 excision, 89
 experimental, 83-84, 86, 90
 fungi causing, 31, 81, 82, 84, 85, 95
 geographical distribution, 81
 grains, 82, 84, 85, 97, 98, 241
 incidence, 78, 79, 126
 incubation period, 125
 laboratory aspects, 78-91
 microscopic appearances, 36
 pain in, 127-129
 radiological appearances, 85, 114-115,
 124-125
 site of lesion, 126
 staining methods, 38
 treatment, 128, 252, 260
- Mycobacterium ulcerans*, 194
- Nephrotic syndrome, association with
 malaria, 273
- Nervous system, in African histoplasmosis,
 104, 124
- Nocardia asteroides*, 12, 16, 22, 31, 36, 38,
 41, 97, 126
 effect of temperature, 171
- Nocardia brasiliensis*, 12, 17, 31, 36, 38, 97,
 114, 125
 action of griseofulvin, 231, 241
 causing mycetoma, 86, 89, 90
 invasive characteristics, 115
- Nocardia caviae*, 12, 17, 22
- Nocardia farcinica*, 126, 270
- Nocardia* spp., causing mycetoma, 81,
 82

- Nocardiosis,
 clinical features, 97
 diagnosis, 31, 82
 microscopic appearances, 36
 pathogenesis, 12, 16
 staining methods, 38, 41
 treatment, 242, 252
- Nomenclature, 19-21, 22-23, 25
- North American blastomycosis, 12, 15, 198
 diagnosis, 31
 effect of temperature, 171
 epidemiology, 132, 198-199, 204
 hamycin in, 247
 2-hydroxystilbamidine in, 243-244
 immunological diagnosis, 60-61
 in Africa, 53, 132, 198
 microscopic appearances, 37
 radiological appearances, 119
 saramycetin in, 247, 267
 skin lesions, 109
 staining methods, 39
 transmission, 137
 treatment, 223, 224
- Nystatin, 131, 212, 213, 227
 resistance to, 219, 240
 route of administration, 222-223
 specific activity, 215, 216
 toxicity, 226
- Orbit, mycoses of, 193
- Pain, in mycetoma, 127-129
- Pathogenesis, of mycoses, 9-25, *see also*
under individual lesions
- Paracoccidioides brasiliensis*, 12, 15, 23, 42, 167
- Penicillin, 243
- Penicillium marneffei*, 51
- Phialophora gougerotii*, 12, 17, 273-275
- Phialophora jeanselmei*, 31, 273-275
- Phialophora pedrosoi*, 100, 203, 204
- Phialophora verrucosa*, 12, 17, 215
- Phycomycosis,
 action of antibiotics, 217, 245
 diagnosis, 31
 effect of temperature, 180-181
 epidemiology, of 179-197, 201-202, 204
 microscopic appearances, 36
 of intestine, 25
 pathogenesis, 12, 16
 radiological appearances, 114
- Phycomycosis—*continued*
 staining methods, 38
 subcutaneous, 12, 16, 36, 38, 99, 179-184, 193-194, 201-202
 clinical features, 99
 epidemiology, 199
 incidence, 181-183
 terminology, 192-193
 treatment, 195-196
- Pimaricin, 212, 213
 administration, 223
 specific activity, 215, 216
 toxicity, 226
- Potassium iodide, 196, 242
- Pyrenochaeta romeroi*, 12, 17, 23, 81, 82
- Radiology,
 of deep mycoses, 113-125
 of mycetoma, 85, 124-125, 126-127
- Rhino-entomophthoromycosis, 179-191
 climatic conditions and, 186-187
 clinical features, 99-100
 diagnosis, 179-180
 epidemiology of, 184-188, 199
 geographical distribution, 186, 187, 195
 incidence, 186
 radiological appearances, 114
 treatment, 196
- Rhinosporidiosis, 12, 17
 microscopic appearances, 37
 radiological appearances, 114
 staining methods, 39
- Rhinosporidium seeberi*, 12, 17, 269
- Rhizopus* spp., 12, 16
- Saramycetin, 215, 233-234, 246-257, 266-267
- Schistosomiasis, 272-273
- Skin lesions, 128
 in African histoplasmosis, 101, 111, 112
 in blastomycosis, 110
- Skin testing in African histoplasmosis, 109-110
- Soil, fungi in, 143, 146, 147, 187-188
- South American blastomycosis, 12, 15, 276
 effect of temperature, 167-168
 immunological diagnosis, 61
 microscopic appearances, 37
 staining methods, 39
- Sporothrix gougerotii*, 273-274
- Sporothrix schenckii*, 12, 17, 23
 action of antibiotics, 215

- Sporothrix schenckii*,
 animal vectors, 152-153
 effect of temperature, 266
 identification, 52, 145
 morphology, 147
 pathogenesis, 148
 virulence, 154-155, 161
- Sporotrichin, 155, 156, 160
- Sporotrichosis, 15, 17
 age and sex incidence, 150-152
 climatic conditions, 154, 163, 164-165,
 166
 clinical features, 144-145
 diagnosis, 113, 159-160
 effect of temperature, 154, 164-167
 epidemiology, 144-158, 199
 factors in development, 153-156
 geographical distribution, 150
 hypersensitivity, 155, 160
 immunological diagnosis, 66, 160
 in animals, 269, 270
 incidence, 150, 161, 162
 occupational, 151-152
 potassium iodide in, 242
 saramycetin in, 247
 seasonal incidence, 162-163, 165
 staining methods, 38
- Steroids, as predisposing factor for can-
 didosis, 140-141
- Streptimidone, 211
- Streptomyces madurac*, 81, 82, 83, 90
 causing mycetoma, 97
- Streptomyces pelletieri*, 81, 82, 83, 89, 90,
 97, 114, 115, 125
- Streptomyces somaliensis*, 81, 82, 83, 125,
 126, 127
 causing mycetoma, 97
 invasive characteristics, 115
- Streptomyces* spp., 12, 17
 causing mycetoma, 31
 immunological identification, 83
- Sulphonamides, 242-243
- Temperature, effect on mycoses, 164-178,
see also under specific mycoses
- Trauma, role in mycotic infections, 152,
 153, 157, 184
- Trichomycin, 212, 213
 specific activity, 215
 toxicity, 226
- Trichophyton rubrum*, 12, 18, 21, 177
- Trichophyton schoenleinii*, 12, 18, 21
- Trichophyton* spp., action of antibiotics, 215
- Trichophyton verrucosum*, 21
- Variotin, 215, 234
- World Health Organization, 276

BRITISH INDIAN SIVA SAIKIAN COLLEGE
 of Obstetrics Gynecology and
 Child Health

LIBRARY MEMORANDUM



